Kosan, Bristol-Myers deal

Simultaneously, Bristol-Myers received an exclusive, worldwide license to Kosan’s epothilone compounds as a backup deal. If the acquisition does not go through, Kosan would receive

Read the full 251 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE